GILD Form 4: Options Exercised and 28,000 Share Sales by CCO Mercier
Rhea-AI Filing Summary
Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025. The filing shows a series of option-related acquisitions and open-market sales in common stock: total reported sales on that date equal 28,000 shares at prices ranging roughly from $117.91 to $119.01, and multiple option exercises/acquisitions at an exercise price of $66.64. Following the reported transactions, the filing lists beneficial ownership levels of common stock as low as 114,168 shares and various counts of options/derivatives remaining outstanding. The Form 4 also discloses that the related options have a four-year vesting schedule with 25% vesting after one year and the remainder vesting quarterly thereafter.
Positive
- Transactions executed under a Rule 10b5-1 trading plan, indicating pre-established compliance documentation
- Vesting schedule disclosed for the non-qualified stock options (four-year schedule; 25% at first anniversary, remainder quarterly)
Negative
- Insider sold 28,000 shares on 08/15/2025 at prices roughly between $117.91 and $119.01, reducing reported beneficial ownership to as low as 114,168 shares
Insights
TL;DR: Insider executed option acquisitions and sold 28,000 shares under a 10b5-1 plan; transactions appear routine and disclosed.
The Form 4 reports coordinated exercises/acquisitions of non-qualified stock options at a $66.64 strike and contemporaneous open-market sales executed under a Rule 10b5-1 plan adopted Feb 20, 2025. Aggregate sales reported on 08/15/2025 total 28,000 shares at prices in the ~$117.91–$119.01 range, which generated material cash proceeds relative to a single-person insider but are not, by themselves, a company-level event. The filing also documents remaining equity and option holdings (common shares and options shown at various post-transaction balances, e.g., 114,168 shares beneficially owned). For investors, these are governance/compliance disclosures rather than operating or financial performance signals.
TL;DR: Transactions executed under a documented 10b5-1 plan with full vesting schedule disclosure — consistent with standard insider liquidity practices.
The Form 4 clearly states the trades were made pursuant to a Rule 10b5-1 trading plan, which provides an affirmative defense to insider trading allegations when properly adopted and followed. The filing includes the vesting schedule for the options (four-year schedule, 25% at year one, remainder quarterly at 6.25%), and provides ranges for sale prices with an offer to supply detailed trade-by-trade pricing on request. Documentation and disclosure appear complete for regulatory compliance; no additional governance issues are identified within the filing itself.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-qualified Stock Option (Right to Buy) | 11,800 | $0.00 | -- |
| Exercise | Non-qualified Stock Option (Right to Buy) | 700 | $0.00 | -- |
| Exercise | Non-qualified Stock Option (Right to Buy) | 11,800 | $0.00 | -- |
| Exercise | Non-qualified Stock Option (Right to Buy) | 700 | $0.00 | -- |
| Exercise | Common Stock | 11,800 | $66.64 | $786K |
| Sale | Common Stock | 11,800 | $118.5044 | $1.40M |
| Exercise | Common Stock | 700 | $66.64 | $47K |
| Sale | Common Stock | 700 | $118.9686 | $83K |
| Exercise | Common Stock | 11,800 | $66.64 | $786K |
| Sale | Common Stock | 11,800 | $118.5089 | $1.40M |
| Exercise | Common Stock | 700 | $66.64 | $47K |
| Sale | Common Stock | 700 | $118.9686 | $83K |
| Sale | Common Stock | 2,800 | $118.5074 | $332K |
| Sale | Common Stock | 200 | $118.965 | $24K |
Footnotes (1)
- The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Sales prices for the transactions reported here range from $117.91 to $118.89. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Sales prices for the transactions reported here range from $118.91 to $119.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or the shareowners upon request. Sales prices for the transactions reported here range from $117.91 to $118.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Sales prices for the transactions reported here range from $118.95 to $118.98. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
